The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Genentech; Incyte; Merck; Transgene

Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation.
 
Arta Monjazeb
No Relationships to Disclose
 
Anita Giobbie-Hurder
No Relationships to Disclose
 
Ana Lako
No Relationships to Disclose
 
Anteneh A. Tesfaye
Consulting or Advisory Role - Exelixis; Ipsen
 
Amanda Stroiney
Consulting or Advisory Role - Outcomes4Me
 
Ryan D. Gentzler
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Salma Jabbour
Research Funding - Merck Sharp & Dohme (Inst); Nestle health science (Inst)
 
Olatunji B. Alese
Consulting or Advisory Role - AstraZeneca; Conjupro Biotherapeutics; Exelixis; Purdue Pharma
Research Funding - Acetylon Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Osama E. Rahma
Leadership - Outcomes4me
Honoraria - Alaunus Global; Clinical Care Options; Leerink; Merck; MI Bioresearch; PRMA Consulting
Consulting or Advisory Role - Alcimed; Celgene; Defined Health; Five Prime Therapeutics; Gfk; Merck; PureTech; Putnam Associates
Research Funding - Amgen (Inst); Merck
Travel, Accommodations, Expenses - Clinical Care Options; Genentech; Merck; PRMA Consulting; PureTech
 
James M. Cleary
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb
Research Funding - Merck; Tesaro
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Roche
 
Elad Sharon
No Relationships to Disclose
 
David Raben
Honoraria - AstraZeneca; BiolineRx
Consulting or Advisory Role - AstraZeneca; Genentech; Merck; Nanobiotix
Travel, Accommodations, Expenses - Nanobiotix
 
Harvey J. Mamon
Honoraria - UpToDate
 
Howard Streicher
No Relationships to Disclose
 
Helen X. Chen
No Relationships to Disclose
 
Mansoor Ahmed
No Relationships to Disclose
 
Evisa Gjini
No Relationships to Disclose
 
Scott Rodig
Honoraria - Bristol-Myers Squibb; Perkin Elmer
Consulting or Advisory Role - AstraZeneca; Perkin Elmer
Research Funding - Affimed Therapeutics; Bristol-Myers Squibb; Kite, a Gilead company; Merck
Patents, Royalties, Other Intellectual Property - Patent pending for use of Anti-galectin1 antibodies for diagnostic use.
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health
Consulting or Advisory Role - Aduro Biotech; Amgen; Bayer; Bristol-Myers Squibb; Celldex; EMD Serono; Genentech/Roche; Incyte; Incyte; Incyte; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Jonathan Daniel Schoenfeld
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Debiopharm Group; Nanobiotix; Tilos Therapeutics
Research Funding - Bristol-Myers Squibb; Merck